160 results on '"Kamat, A.M."'
Search Results
2. The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance
Catalog
Books, media, physical & digital resources
3. Challenging the paradigm of BCG unresponsive bladder cancer: Does additional BCG have an effect?
4. Impact of systemic therapy in clinical T1 small-cell neuroendocrine carcinoma of the bladder
5. Urachal (U) and Non-Urachal (NU) Adenocarcinomas (adenoCA) of the bladder: A comparative Comprehensive Genomic Profiling (CGP) study
6. Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial
7. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
8. Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder
9. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
10. Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses.
11. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
12. Bacillus calmette-guerin vs immediate radical cystectomy in eau defined very high-risk non-muscle invasive bladder cancer patients
13. Association of age with non-muscle-invasive bladder cancer: A biological basis for epidemiological disparities?
14. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III
15. Systematic Review and Meta-Analysis of Response Rates in BCG-unresponsive Non–Muscle-Invasive Bladder Cancer: a Consensus Statement From the International Bladder Cancer Group.
16. Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group
17. Reduced Dose Intravesical Bacillus Calmette-Guerin: Why It Might Not Matter
18. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
19. A0863 - Urachal (U) and Non-Urachal (NU) Adenocarcinomas (adenoCA) of the bladder: A comparative Comprehensive Genomic Profiling (CGP) study
20. A0743 - Impact of systemic therapy in clinical T1 small-cell neuroendocrine carcinoma of the bladder
21. A0739 - Challenging the paradigm of BCG unresponsive bladder cancer: Does additional BCG have an effect?
22. A0742 - The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance
23. A0583 - Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial
24. Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)
25. Management, surveillance patterns, and costs associated with low-grade Papillary (Ta) non-muscle invasive bladder cancer
26. The updated EAU prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin
27. Accuracy of novel urinary biomarker tests for diagnosis and surveillance of NMIBC: A systematic review, diagnostic test accuracy and network meta-analyses
28. 718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
29. Data sharing under the general data protection regulation: Time to harmonize law and research ethics?
30. Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
31. All HG NMIBC is high risk: BCG response in HG Ta lesions
32. Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
33. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis
34. 100 years of Bacillus Calmette-Guerin immunotherapy: from cattle to COVID-19
35. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?
36. Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis
37. Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG)
38. What is the prognostic importance of urothelial and non-urothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? Systematic review
39. PCN42 TREATMENT PATTERNS AND SURVIVAL AMONG PATIENTS WITH BCG UNRESPONSIVE HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER: AN ASSESSMENT OF THE SEER-MEDICARE DATA
40. PCN62 DISEASE BURDEN ASSOCIATED WITH PROGRESSION IN PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER RECEIVING BLADDER PRESERVING THERAPIES AFTER ADEQUATE BCG INDUCTION: A SEER-MEDICARE DATABASE STUDY
41. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
42. Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)
43. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis
44. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer
45. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
46. Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
47. Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)
48. Outcomes of radical cystectomy following implementation of enhanced recovery after surgery protocols: A systematic review
49. A0328 - Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)
50. A0151 - Management, surveillance patterns, and costs associated with low-grade Papillary (Ta) non-muscle invasive bladder cancer
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.